Mouse sarcomas treated with CpG and RT were all assigned to SIC D and E while sarcomas with no treatment were assigned to the less-inflamed SICs A, B, and C. Using CIBERSORTx and data from The Cancer Genome Atlas (TCGA), we compared the immune infiltration in human UPS samples from each SIC with murine p53/MCA tumors from each treatment group (Figure 4C). This evidence concerns the gene TP53 and sarcoma.